神经科学家发现，Ozempic和Wegovy等GLP-1激动剂药物可能通过作用于大脑特定区域来抑制对食物、酒精及其他成瘾物质的渴望1。这一机制涉及大脑的侧隔膜（lateral septum）区域，该区域密集分布GLP-1受体，可充当奖赏思考与追求之间的控制枢纽1。
侧隔膜主要从海马体获得初级输入，与海马体协同处理"我在哪里、现在是何时"等空间-时间信息1。这个脑区包含对奖赏产生强烈反应的位置细胞，能够有效地将"这个地方什么是好的"信息整合到空间-时间框架中1。研究表明，GLP-1在侧隔膜的直接激活可减少小鼠的食物消耗和酒精消耗1。
人类研究表明GLP-1激动剂可减少酒精消耗，而动物研究则显示这类药物可降低对可卡因、安非他明、阿片类和尼古丁的使用1。这些GLP-1激动剂通过模拟GLP-1激素的作用来发挥效果，刺激胰岛素释放、减缓消化并增加饱腹感1。这一发现为成瘾和肥胖症的治疗开辟了新的治疗途径1。
Scientists have identified a previously underappreciated region of the brain that may explain how medications like Ozempic reduce cravings for food, alcohol, and other addictive substances.1 The lateral septum, a brain area densely populated with GLP-1 receptors, acts as a control hub between thinking about rewards and pursuing them.1 Researchers at the University of Otago, led by Robert Munn and his laboratory, discovered and validated that GLP-1 agonists—drugs that mimic the GLP-1 hormone—work by directly activating this region to suppress consumption.1
GLP-1 agonists including Ozempic and Wegovy stimulate insulin release, slow digestion, and increase feelings of fullness.1 Clinical evidence shows these medications reduce alcohol consumption in humans, while animal studies demonstrate they can decrease use of cocaine, amphetamine, opioids, and nicotine.1 The lateral septum receives most of its primary input from the hippocampus and, together with that region, processes information about location and timing.1 Significantly, this area contains place cells that respond strongly to rewards, effectively adding information about "what is good in this location" to spatial and temporal data.1 Direct activation of GLP-1 in the lateral septum reduced both food and alcohol consumption in mice during testing.1
评论
还没有评论，欢迎留下第一条。